Eagle Pharmaceuticals Inc. (EGRX) 37.63 $EGRX 5 Stocks

Eagle Pharmaceuticals Inc. (EGRX) 37.63 $EGRX

5 Stocks With Jaw-Dropping Growth Potential
George Budwell, The Motley Fool - Motley Fool - Sat Feb 28, 8:04AM CST
With the U.S. stock market hitting record highs of late and red hot sectors like health care sporting some jaw-dropping premiums, it's getting harder and harder to find stocks with compelling valuations. That being said, there are still a handful of...
VRX: 198.71 (-5.24), FLML: 15.37 (-0.78), PTX: 11.78 (+0.28), AZN: 66.27 (-1.91), TEVA: 56.40 (-0.11), GSK: 46.73 (-0.87), EGRX: 37.63 (-0.37), SNY: 47.42 (-0.94), ARDX: 15.66 (-0.42), IG: 9.01 (-0.42)

Nasdaq stocks posting largest volume increases
AP - Fri Feb 20, 5:00PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 26.24 (+0.27), CLSN: 2.82 (-0.05), SBBX: 10.87 (-0.18), NDLS: 17.49 (-0.58), HOTR: 2.04 (-0.03), EGRX: 37.63 (-0.37), ONVI: 4.50 (unch), JAXB: 10.59 (-0.11), BWFG: 19.24 (+0.74), FBSS: 16.70 (-0.85)

Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 20, 5:00PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RESN: 11.82 (+0.77), UIHC: 23.41 (-0.24), UEIC: 55.16 (-0.70), ALDX: 10.52 (+0.02), AXDX: 18.15 (+0.21), ANGI: 6.80 (+0.08), VNDA: 10.47 (-0.24), FUEL: 10.34 (+0.02), NDLS: 17.49 (-0.58), NMIH: 7.32 (-0.08), EGRX: 37.63 (-0.37)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 11:45AM CST

BNSO: 1.45 (-0.01), BONE: 3.44 (-0.24), FUEL: 10.34 (+0.02), ASTI: 1.43 (-0.02), AHS: 20.93 (-0.22), AXN: 1.49 (+0.37), EGRX: 37.63 (-0.37), NBG: 1.43 (-0.08), GTT: 16.27 (-0.18), WBAI: 14.50 (+0.70), GENE: 4.86 (-1.39), EGLT: 14.05 (-1.13), SAAS: 10.97 (-0.52), CLRX: 1.15 (-0.10), CAS: 3.40 (-0.05), NDLS: 17.49 (-0.58), TRUE: 16.84 (-0.33), HOTR: 2.04 (-0.03), SZMK: 7.75 (-0.47), BLDR: 6.06 (+0.10)

Traders smitten with tiny thinly-traded biotechs
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:44AM CST

GENE: 4.86 (-1.39), HTBX: 7.35 (+0.53), SGNL: 2.70 (-0.11), ROSG: 3.24 (-0.04), TTPH: 37.09 (-1.80), ONCY: 0.90 (-0.15), CLRX: 1.15 (-0.10), MELA: 1.83 (+0.02), AKAO: 10.32 (-0.11), WGBS: 4.71 (-0.03), EGRX: 37.63 (-0.37)

Teva to Commercialize Eagle's Cancer Drug in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 12:20PM CST
Teva (TEVA) signed a deal to commercialize Eagle's bendamustine hydrochloride rapid infusion candidate in the U.S.
IPXL: 39.08 (-1.00), ACT: 289.92 (-5.78), TEVA: 56.40 (-0.11), EGRX: 37.63 (-0.37)

Eagle Pharmaceuticals incurs higher net loss of USD5.5m for three month period ended 31 December 2014
M2 - Wed Feb 18, 6:49AM CST
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) disclosed on Tuesday that it recorded a net loss of USD5.5m (USD0.39 per basic and diluted common share) for the transitional three-month period ended 31 December 2014 (the stub period).
EGRX: 37.63 (-0.37)

Eagle Pharmaceuticals reports 4Q loss
Automated Insights - Wed Feb 18, 4:03AM CST
WOODCLIFF LAKE, N.J. (AP) _ Eagle Pharmaceuticals Inc. (EGRX) on Wednesday reported a loss of $5.5 million in its fourth quarter.
EGRX: 37.63 (-0.37)

Eagle Pharmaceuticals beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 3:44PM CST

EGRX: 37.63 (-0.37)

Eagle Pharmaceuticals, Inc. Reports Financial Results for Three Month Period Ended December 31, 2014
Business Wire - Tue Feb 17, 3:02PM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company" (Nasdaq:EGRX) today announced its financial results for the transitional three-month period ended December 31, 2014 (the "stub period" . This stub period resulted from the previously-announced change in Eagle's year end from September 30 to December 31. The company will report financial results of the first quarter of 2015 in May.
EGRX: 37.63 (-0.37)

Why Shares of Eagle Pharmaceuticals Inc. Ripped Higher
George Budwell, The Motley Fool - Motley Fool - Tue Feb 17, 12:31PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What:  Shares of developmental-stage biopharma  Eagle...
TEVA: 56.40 (-0.11), EGRX: 37.63 (-0.37)

Eagle and Teva team up in blood cancer
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:05AM CST

TEVA: 56.40 (-0.11), EGRX: 37.63 (-0.37)

Eagle Pharmaceuticals to Hold Conference Call at 8:30 a.m. EST Today to Discuss Licensing Agreement with Teva to Commercialize Eagle's Rapid Infusion Bendamustine
Business Wire - Tue Feb 17, 6:05AM CST
Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company" (Nasdaq:EGRX), will hold a conference call to discuss its newly-disclosed license agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) for EP-3102, Eagle's bendamustine hydrochloride (HCl) rapid infusion product. Interested parties may access the call as follows:
TEVA: 56.40 (-0.11), EGRX: 37.63 (-0.37)

Teva and Eagle Pharmaceuticals Announce Teva's License to Commercialize Eagle's Bendamustine Rapid Infusion Product
Business Wire - Tue Feb 17, 6:01AM CST
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) today announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle's bendamustine hydrochloride (HCl) rapid infusion product for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva.
TEVA: 56.40 (-0.11), EGRX: 37.63 (-0.37)